オマリズマブ
参考資料 > 引用

↑  “Xolair- omalizumab injection, solution Xolair PFS- omalizumab injection, solution”. DailyMed (11 May 2020). 6 December 2020閲覧。
↑  Schulman ES (October 2001). “Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders”. Am J Respir Crit Care Med 164 (8 Pt 2):  S6–11. doi:10.1164/ajrccm.164.supplement_1.2103025. PMID 11704611.
1 2 3  “Anti-IgE Antibodies for the Treatment of IgE-mediated Allergic Diseases”. Adv Immunol. Advances in Immunology 93:  63–119. (2007). doi:10.1016/S0065-2776(06)93002-8. ISBN 9780123737076. PMID 17383539.
1 2  “ゾレア皮下注用75mg／ゾレア皮下注用150mg 添付文書”. www.info.pmda.go.jp. 2021年3月27日閲覧。
1 2 3  Davydov, Liya (2005-01-15). “Omalizumab (Xolair) for Treatment of Asthma”. American Family Physician 71 (2):  341. ISSN 0002-838X. PMID 15686303. https://www.aafp.org/afp/2005/0115/p341.html.
↑  Pocket guide for asthma management and prevention. Global Initiatives for Asthma. 2013. “Archived copy”. 2013年5月21日時点のオリジナルよりアーカイブ。2013年7月7日閲覧。
1 2  Urgert, M.C.; Elzen, M.T.; Knulst, A.C.; Fedorowicz, Z.; Zuuren, E.J. (22 July 2015). “Omalizumab in patients with chronic spontaneous urticaria: a systematic review and assessment”. British Journal of Dermatology 173 (2):  404–415. doi:10.1111/bjd.13845. PMID 25891046.
1 2  Bernstein, Jonathan A.; Kavati, Abhishek; Tharp, Michael D.; Ortiz, Benjamin; MacDonald, Karen; Denhaerynck, Kris; Abraham, Ivo (16 February 2018). “Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence”. Expert Opinion on Biological Therapy 18 (4):  425–448. doi:10.1080/14712598.2018.1438406. PMID 29431518.
↑  Zhao, Zuo-Tao; Ji, Chun-Mei; Yu, Wen-Jun; Meng, Ling; Hawro, Tomasz; Wei, Ji-Fu; Maurer, Marcus (June 2016). “Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials”. Journal of Allergy and Clinical Immunology 137 (6):  1742–1750.e4. doi:10.1016/j.jaci.2015.12.1342. PMID 27040372.
↑  Fanta CH (March 2009). “Asthma”. N. Engl. J. Med. 360 (10):  1002–14. doi:10.1056/NEJMra0804579. PMID 19264689.
↑  “Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells”. Eur. J. Immunol. 33 (4):  1030–40. (April 2003). doi:10.1002/eji.200323185. PMID 12672069.
↑  “Omalizumab and the risk of malignancy: results from a pooled analysis”. The Journal of Allergy and Clinical Immunology 129 (4):  983–9.e6. (April 2012). doi:10.1016/j.jaci.2012.01.033. PMID 22365654.
↑  Chang TW (February 2000). “The pharmacological basis of anti-IgE therapy”. Nat. Biotechnol. 18 (2):  157–62. doi:10.1038/72601. PMID 10657120.
1 2 3  “Anti-IgE as a mast cell-stabilizing therapeutic agent”. The Journal of Allergy and Clinical Immunology 117 (6):  1203–12. (June 2006). doi:10.1016/j.jaci.2006.04.005. PMID 16750976.
↑  “Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody”. Journal of Immunology 158 (3):  1438–45. (February 1997). PMID 9013989.
↑  “Omalizumab treatment downregulates dendritic cell FcepsilonRI expression”. The Journal of Allergy and Clinical Immunology 112 (6):  1147–54. (December 2003). doi:10.1016/j.jaci.2003.10.003. PMID 14657874. https://zenodo.org/record/1259077.
↑  Scheinfeld N (2005). “Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody”. Dermatol. Online J. 11 (1):  2. PMID 15748543.
↑  “Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy”. Clin. Exp. Allergy 35 (4):  408–16. (April 2005). doi:10.1111/j.1365-2222.2005.02191.x. PMID 15836747.
1 2  “The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation”. The Journal of Allergy and Clinical Immunology 115 (3):  459–65. (March 2005). doi:10.1016/j.jaci.2004.11.053. PMID 15753888.
↑  “Effects of omalizumab on markers of inflammation in patients with allergic asthma”. Allergy 64 (12):  1728–36. (December 2009). doi:10.1111/j.1398-9995.2009.02201.x. PMID 19839977.
↑  “Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody”. Thorax 62 (3):  276–7. (March 2007). doi:10.1136/thx.2004.035519. PMC 2117163. PMID 17329558. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117163/.
↑  “Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE”. Ann Allergy Asthma Immunol 104 (6):  537–9. (June 2010). doi:10.1016/j.anai.2010.04.011. PMID 20568389.
1 2  “Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab”. The Journal of Allergy and Clinical Immunology 123 (3):  704–5. (March 2009). doi:10.1016/j.jaci.2008.11.035. PMC 4784096. PMID 19152970. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784096/.
↑  “Is interstitial cystitis an allergic disorder?: A case of interstitial cystitis treated successfully with anti-IgE”. Int. J. Urol. 13 (5):  631–4. (May 2006). doi:10.1111/j.1442-2042.2006.01373.x. PMID 16771742.
↑  “Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab”. The Journal of Allergy and Clinical Immunology 120 (4):  979–81. (October 2007). doi:10.1016/j.jaci.2007.07.041. PMID 17931567.
↑  de Llano LP, Vennera Mdel C, Álvarez FJ, Medina JF, Borderías L, Pellicer C, González H, Gullón JA, Martínez-Moragón E, Sabadell C, Zamarro S, Picado C; Spanish Registry (April 2013). “Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry”. J Asthma 50 (3):  296–301. doi:10.3109/02770903.2012.757780. PMID 23350994.
↑  “Against all odds: anti-IgE for intrinsic asthma?”. Thorax 69 (1):  94–6. (May 2013). doi:10.1136/thoraxjnl-2013-203738. PMC 3888607. PMID 23709757. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888607/.
↑  “Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria”. N Engl J Med 368 (10):  924–35. (March 2013). doi:10.1056/NEJMoa1215372. PMID 23432142.
↑  “Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy”. The Journal of Allergy and Clinical Immunology 132 (1):  101–9. (July 2013). doi:10.1016/j.jaci.2013.05.013. PMID 23810097.
↑  “Monomeric IgE and mast cell development, survival and function”. Mast Cell Biology. Advances in Experimental Medicine and Biology. 716. (2011). 29–46. doi:10.1007/978-1-4419-9533-9_3. ISBN 978-1-4419-9532-2. PMID 21713650
↑  “Community register of medicinal products for human use”. ec.europa.eu. 2014年4月20日時点のオリジナルよりアーカイブ。2021年3月27日閲覧。